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Case report
Rasburicase induced severe hemolysis and methemoglobinemia in a
Caucasian patient complicated by acute renal failure and ARDS
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A B S T R A C T
Rasburicase is a recombinant urate-oxidase enzyme and is a very important medication for tumor lysis syndrome. Methemoglobinemia and hemolysis are known side
effects of rasburicase that result from oxidative stress caused by hydrogen peroxide, a byproduct generated during the breakdown of uric acid to allantoin. Patients
with G6PD deficiency have a decreased tolerance to oxidative stress and are therefore at a greater risk of hemolysis and methemoglobinemia with rasburicase. Our
patient is a 56-year-old Caucasian male with a recent diagnosis of grade 2-3a non-Hodgkin's lymphoma who presented to our emergency department with shortness
of breath and dark discoloration of urine. Patient was discharged 36 hours ago from our hospital after he was given a first course of R-CHOP regimen and a dose of
rasburicase. On further evaluation, patient was found to have severe anemia with hemolytic picture, hyperkalemia and acute kidney injury. He also had a discrepancy
of the transcutaneous saturation (75%) and the saturation in an arterial blood gas value (99%). His methemoglobin level was found to be 11.9%. We were aware that
methylene blue is a contraindication in patients with G6PD deficiency but considering patient being Caucasian and low risk for it and his deteriorating respiratory
condition, it was decided to offer the treatment and patient received 1 dose of methylene blue which failed to improve his methemoglobinemia. He was also given
vitamin C and 8 units of packed red blood cell throughout his stay in the hospital. Patient's hospital course was complicated by ARDS needed to be on mechanical
ventilation support for 4 days and acute renal failure secondary to pigment nephropathy and acute tubular necrosis which required a hemodialysis support. Even if
rasburicase induced methemoglobinemia and hemolysis are not very common complications, clinicians who prescribe and follow patients should detect this serious
complication early and manage it accordingly. Our case can be used as a reminder that patients should be followed closely and given the right instructions on
discharge to treat these complications which are associated with severe consequences. It is also vital to assume a diagnosis of G6PD deficiency until proven otherwise
in a patient who presents with rasburicase induced hemolysis and avoid administration of methylene blue even if the patient is from a low risk ethnicity for G6PD as
in our patient.
1. Introduction
Tumor lysis syndrome (TLS) is an oncologic emergency caused by
massive tumor cell lysis with the release of large amounts of potassium,
phosphate, and nucleic acids into systemic circulation. Catabolism of
these nucleic acids into uric acid leads to hyperuricemia [1,2,11]. TLS
most commonly occurs after the initiation of cytotoxic therapy in pa-
tients with high-grade lymphomas and acute lymphoblastic leukemia.
However, TLS can occur spontaneously and with other tumor types
with high proliferative rates, large tumor burden, or high sensitivity to
cytotoxic therapy [11]. Rasburicase is a recombinant urate-oxidase
enzyme which converts uric acid into allantoin, an inactive, soluble
metabolite of uric acid [4]. Previous studies revealed that rasburicase
reduces serum urate levels faster and with less acute kidney injury
compared to allopurinol, so it is commonly used in patients with clin-
ical TLS or in patients who are at high risk for TLS as is the case with
high-grade lymphomas and acute lymphoblastic leukemia [1,5,6].
Methemoglobinemia and hemolysis are known side effects of
rasburicase that result from oxidative stress caused by hydrogen per-
oxide, a byproduct generated during the breakdown of uric acid to al-
lantoin. Patients with G6PD deficiency have a decreased tolerance to
oxidative stress and are therefore at a greater risk of hemolysis and
methemoglobinemia with rasburicase [6,8]. We present a Caucasian
patient of north European descent with rasburicase induced severe
hemolytic anemia and methemoglobinemia with a newly diagnosed
glucose 6 phosphate dehydrogenase deficiency ().
2. Case report
A 56-year-old Caucasian male of north American descent with re-
cent diagnosis of grade 3a follicular lymphoma, tobacco and marijuana
use disorder presented to the emergency department with shortness of
breath and hematuria. He was diagnosed with grade 3 follicular lym-
phoma two weeks prior to this admission when he presented to our
hospital with abdominal pain and back pain associated with six-week
duration of abdominal distention, decreased appetite and 14-kilogram
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weight loss. He underwent CT scan of abdomen at that time showing
bulky retroperitoneal and mesenteric lymphadenopathy consistent with
lymphoma and large volume ascites (Fig. 1). CT chest was also per-
formed showing normal lung parenchyma with no involvement. The
patient underwent CT guided core biopsy showing WHO grade 3a fol-
licular lymphoma. Oncology was consulted, and he underwent a bone
marrow biopsy showing normocellular bone marrow with no involve-
ment by lymphoma. Peripheral blood revealed slight normocytic an-
emia but was otherwise normal. At the time of the first admission,
hemoglobin was 13 g/dl, white blood cell count was 10300 per cubic
millimeter, uric acid 5.7mg/dl, LDH 662 u/l, bilirubin 1.1mg/dl ad
alkaline phosphatase was 201U/L. Electrolytes were within the normal
range. Due to the high-grade nature of the lymphoma, the patient was
admitted to the hospital to start chemotherapy. After appropriate
counseling, he received Rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone. Twenty-four hours after receiving the first
dose of chemotherapy, he had a significant increase in uric acid and
phosphorus levels raising the concern for possible tumor lysis syn-
drome. He was given one dose of Rasburicase and his uric acid and
phosphorus normalized. He was asymptomatic and was discharged
home.
Around 12 hours after the administration of Rasburicase, he began
to experience shortness of breath, dizziness, and noticed that his urine
became dark. He fell at home and injured his right arm but sustained no
head trauma. He then noticed bloody urine, increased weakness and
shortness of breath and he came to the emergency room (ER) for eva-
luation.
On arrival, patient denied any chest pain, cough, fever, chills,
nausea or vomiting. He was alert and oriented, tachycardic and in mild
respiratory distress. Oxygen saturation was around 75%. He had mild
abdominal distension. There was decreased air entry in the right lower
posterior chest.
His laboratory findings are as follows:
Normal At admission 36 hours before
WBC (K/cubic mm) 4–11 45.4 15.1
Hemoglobin (g/dl) 13–15 7.9 13.4
Potassium (meq/l) 3.5–5 7.1 4.8
Creatinine (mg/dl) 0.6–1.1 1.11 0.8
Phosphorous (mg/dl) 2.5–4.5 3.9 3.2
LDH (u/l) 87–241 3800 740
Bilirubin (mg/dl) 0.2–1 7 1
Haptoglobin 30–200 26 –
At initial evaluation, he was in mild distress, but his transcutaneous
saturation was around 75%. He was placed on bi-valve positive air way
pressure from the emergency room. CT of the chest with pulmonary
embolism protocol was negative and there was no abnormal pulmonary
infiltrate. Arterial blood gas was ordered, and it showed a PH of 7.51,
PCO2 of 35 and PO2 of 565 and oxygen saturation of 100%. The dis-
crepancy of the transcutaneous saturation and the arterial blood gas
value lead us for a possible diagnosis of methemoglobinemia secondary
to Rasburicase and methemoglobin and carboxyhemoglobin levels were
ordered. Laboratory values with time after admission is shown in
Table 1.
The methemoglobin level was found to be 11.9% and his carbox-
yhemoglobin level was 7.5%. Rasburicase induced methemoglobinemia
with severe hemolytic anemia, hyperkalemia and acute kidney injury
was diagnosed. Since Rasburicase mostly causes hemolysis in patients
with glucose 6 phosphate dehydrogenase deficiency (G6PD), quantita-
tive test for it was sent even if our patient is a Caucasian male of north
European descent with less probability of abnormal test. Hemoglobin
was followed regularly and patient was placed on supportive manage-
ment including steroids. But his respiratory condition worsened, and it
was decided to start the patient with methylene blue. We were aware
that methylene blue is contraindicated in patients with G6PD deficiency
but considering low risk race for G6PD deficiency and his deteriorating
respiratory condition, it was decided to offer the treatment for the pa-
tient.
Patient was counselled about the situation and he decided he
wanted the treatment and he was given one dose of 1mg/kg of me-
thylene blue and he was also started with vitamin C and continued with
IV fluid. Methemoglobin level was remeasured 2 hours after adminis-
tration of the methylene blue, but patient didn't show any clinical or
biochemical improvement. He was continued with supportive care and
blood transfusion. His methemoglobin level gradually came down to
1.9% and carboxyhemoglobin level to 4%. The G6PD level came back
slightly lower than normal which makes it an abnormal test since the
expected result in acute hemolysis is normal to higher than normal
Fig. 1. Laboratory values at admission and 36 hours before (Last discharge
from hospital).
Table 1
Laboratory values with time after admission.
Normal Before Rasburicase Admission 12 hours 24 hours 36 hours 48 hours 60 hours
WBC, K/cubic mm 4–11 15.1 45.4 46.6 37.5 36.2 33.6 25.8
Hgb, g/dl 13–15 13.4 7.9 6.1 7.1 7.5 7.6 7.3
Potassium, meq/l 3.5–5 4.4 7.1 5.4 5.2 4.2 3.7 3.5
Creatinine, mg/dl 0.6–1.1 0.74 1.1 1.32 1.60 1.72 2.26 3.82
Phosphorous, mg/dl 2.5–4.5 3.6 3.2 3.9 5.2 5.5 4.9 4
LDH, u/l 87–241 743 3800 5103 5650 5150 2340 1066
Bilirubin, mg/dl 0.2–1 1.2 7 6.3 4 2.7 1.3 1.1
Uric acid, mg/dl 3.5–7.2 7.1 1.2 3 3 3.1 3.1 4.1
Haptoglobin, mg/dl 30–200 – 26 26 27 26 100 165
Methemoglobin, % 0–1.5% – 11.1 11.9 6.9 3.1 1.9 1.8
Carbon monoxide, % 0–3% – 7.5 6.9 5.8 4.6 4.1 3.9
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values. Patient subsequently developed acute respiratory distress syn-
drome because of repeated blood transfusions due to severe anemia
secondary to rasburicase induced hemolysis and IV fluid administration
and he was intubated, and mechanical ventilation support was given.
He needed to stay on mechanical ventilation for 4 days and was ex-
tubated. The extent of the hemolysis due to rasburicase was so severe
that patient needed around 8 units of blood and he developed acute
renal failure due to pigment nephropathy and acute tubular necrosis for
which he was placed on hemodialysis throughout his stay in the hos-
pital.
3. Discussion
Rasburicase is a recombinant urate-oxidase enzyme, which converts
uric acid to allantoin which is an inactive and soluble metabolite of uric
acid. It does not inhibit the formation of uric acid [1]. Rasburicase has
black box warnings as it may cause serious and fatal hypersensitivity
reactions including anaphylaxis, hemolysis in patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, and methemoglobinemia
[5]. Clinicians who prescribe or follow patients who are given ras-
buricase should be able to recognize and promptly manage hemolysis
and methemoglobinemia associated with rasburicase as it is a serious
complication with a severe consequence. Our patient had a discrepancy
in the transcutaneous saturation and the saturation in the arterial blood
gas value which tipped us for a possibility of methemoglobinemia
secondary to Rasburicase.
He also had a drop of around 5.5mg/dl of hemoglobin in 36 hours
which also gave us another clue that the patient has a complication
from the rasburicase. Screening patients at high risk of glucose-6-
phosphate dehydrogenase (G6PD) deficiency, individuals of African
and Mediterranean descent, is recommended prior to initiation of ras-
buricase even if it is not done frequently in practice [2,3,7,9,10]. We
were aware that methylene blue is contraindicated in patients with
G6PD deficiency but considering patient being Caucasian of European
descent and low risk for it and his deteriorating respiratory condition, it
was decided to offer the treatment for him. On the other hand, it is also
suggested that a high index of suspicion of G6PD deficiency is also
crucial in a patient who develops methemoglobinemia or hemolytic
anemia following rasburicase therapy, irrespective of ethnic origin
[1,2,10,12,13].
G6PD deficiency is associated with NADPH deficiency, and methy-
lene blue is dependent on NADPH to reduce methemoglobin to he-
moglobin. This renders methylene blue ineffective in G6PD-deficient
patients, and it may aggravate methemoglobinemia at high doses by
oxidizing hemoglobin [4,12,14]. Methemoglobin is generated when
hemoglobin iron is oxidized from the ferrous (Fe2þ) to the ferric (Fe3þ)
state. Administered methylene blue is converted to leukomethylene
blue by the NADPH-dependent methemoglobin reductase system,
which then transfers an electron to ferric iron reducing it to ferrous iron
[3]. In retrospect, it would have been wiser not to give our patient the
methylene blue considering his presentation with severe hemolysis and
the low G6PD level that was demonstrated in the laboratory result
which came back after 3 days even if patient was actively in hemolysis
when the blood sample was taken. Most previously reported cases of
rasburicase induced hemolysis and methemoglobinemia with G6PD
deficiency were males just like our patient which could be explained by
the X-linked mode of inheritance. But the condition was also reported in
females [9]. We also used ascorbic acid on our patient. Ascorbic acid
has an antioxidant effect not dependent on NADPH and is a safe and
effective treatment for methemoglobinemia especially for patients with
G6PD deficiency [1,4,6]. Rasburicase induced methemoglobinemia
could develop as early as 2 hours after drug administration but our
patient started to have symptoms 12 hours after rasburicase was given.
This has a very important implication when patients are treated with
rasburicase in an outpatient setting [2,3]. It is suggested to observe
patients for at least 6 hours and then give proper instructions for the
next 24 hours. Our patient was advised about the risks of rasburicase
and was observed for about 6 hours but stayed at home 24 hours more
after he started to have the symptoms which further complicated his
condition.
Previous literature has shown that there is no apparent relationship
between the dose of rasburicase administered and the peak methe-
moglobin level or the lowest hemoglobin level [3,8]. Most of the cases
in literature responded for treatment within 3–7 days and our patient
has responded for the treatment in that time range but he has more
complications including ARDS and requirement for mechanical venti-
lation support, multiple transfusions and acute renal failure needing
hemodialysis. Even if rasburicase induced methemoglobinemia and
hemolysis are not very common complications, clinicians who prescribe
and follow patients should detect this serious complication early and
manage it accordingly. Our case can be used as a reminder that patients
should be followed and given the right instructions on discharge to treat
this complication which is associated with severe consequences.
4. Conclusion
Rasburicase is a recombinant urate-oxidase enzyme and is a very
important medication for tumor lysis syndrome. It has black box
warnings as it may cause serious and fatal hypersensitivity reactions
including anaphylaxis, hemolysis in patients with glucose-6-phosphate
dehydrogenase (G6PD) deficiency, and methemoglobinemia. Even if
rasburicase induced methemoglobinemia and hemolysis are not very
common complications, clinicians who prescribe and follow patients
should detect this serious complication early and manage it accord-
ingly. Our case can be used as a reminder that patients should be fol-
lowed closely and given the right instructions on discharge to treat
these complications which are associated with severe consequences. It
is also vital to assume a diagnosis of G6PD deficiency until proven
otherwise in a patient who presents with rasburicase induced hemolysis
and avoid administration of methylene blue even if the patient is from a
low risk ethnicity like Caucasian as in our patient.
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